Brief: Veru Enters Clinical Supply Agreement With Novo Nordisk For Phase 2B Plateau Study - SEC Filing
BRIEF-Veru Enters Clinical Supply Agreement With Novo Nordisk For Phase 2B Plateau Study - SEC Filing June 4 (Reuters) - Veru Inc VERU.O:
VERU - ENTERS CLINICAL SUPPLY AGREEMENT WITH NOVO NORDISK FOR PHASE 2B PLATEAU STUDY - SEC FILING
VERU - NOVO NORDISK TO SUPPLY WEGOVY AT NO CHARGE FOR VERU PHASE 2B STUDY - SEC FILING
VERU - TO PROVIDE NOVO NORDISK WITH INSIGHTS AND UPDATES ON OBESITY TRIAL DESIGN - SEC FILING
VERU - GRANTS NOVO NORDISK RIGHT OF FIRST NEGOTIATION FOR ENOBOSARM IN COMBINATION WITH ANY NOVO'S GLP-1 PRODUCTS
Source text: [ID:n0001437749-26-019478]
Further company coverage: VERU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veru
See all newsUS STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Oppenheimer upbeat on Veru, says 'come for the lean mass, stay for the muscle function'
Veru Inc. reports results for the quarter ended June 30 - Earnings Summary